Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine.

De Lorenzo C, Paciello R, Riccio G, Rea D, Barbieri A, Coppola C, Maurea N.

Onco Targets Ther. 2018 Apr 19;11:2241-2250. doi: 10.2147/OTT.S157294. eCollection 2018.

2.

Toxicology of Trastuzumab: An Insight into Mechanisms of Cardiotoxicity.

An J, Sheikh MS.

Curr Cancer Drug Targets. 2019;19(5):400-407. doi: 10.2174/1568009618666171129222159.

PMID:
29189161
3.

Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.

Fedele C, Riccio G, Coppola C, Barbieri A, Monti MG, Arra C, Tocchetti CG, D'Alessio G, Maurea N, De Lorenzo C.

Breast Cancer Res Treat. 2012 Jun;133(2):511-21. doi: 10.1007/s10549-011-1783-9. Epub 2011 Sep 27.

PMID:
21947749
4.

Cardiotoxicity of novel HER2-targeted therapies.

Sendur MA, Aksoy S, Altundag K.

Curr Med Res Opin. 2013 Aug;29(8):1015-24. doi: 10.1185/03007995.2013.807232. Epub 2013 Jun 7. Review.

PMID:
23692263
5.

Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.

Fedele C, Riccio G, Malara AE, D'Alessio G, De Lorenzo C.

Breast Cancer Res Treat. 2012 Jul;134(2):595-602. doi: 10.1007/s10549-012-2103-8. Epub 2012 Jun 7.

PMID:
22674190
6.

Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.

Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller K, Andre F, Burris HA 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, Sliwkowski MX.

Clin Cancer Res. 2014 Jan 15;20(2):456-68. doi: 10.1158/1078-0432.CCR-13-0358. Epub 2013 Oct 4.

7.

Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.

Yamashita-Kashima Y, Shu S, Harada N, Fujimoto-Ouchi K.

Oncol Rep. 2013 Sep;30(3):1087-93. doi: 10.3892/or.2013.2547. Epub 2013 Jun 19.

PMID:
23783223
8.

Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes.

Kurokawa YK, Shang MR, Yin RT, George SC.

Toxicol Lett. 2018 Mar 15;285:74-80. doi: 10.1016/j.toxlet.2018.01.001. Epub 2018 Jan 2.

PMID:
29305325
9.

Effects of Trastuzumab Emtansine (T-DM1) on QT Interval and Safety of Pertuzumab Plus T-DM1 in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Gupta M, Wang B, Carrothers TJ, LoRusso PM, Chu YW, Shih T, Loecke D, Joshi A, Saad O, Yi JH, Girish S.

Clin Pharmacol Drug Dev. 2013 Jan;2(1):11-24. doi: 10.1002/cpdd.9. Epub 2013 Feb 26.

PMID:
27121556
10.
11.

Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.

Lu D, Burris HA 3rd, Wang B, Dees EC, Cortes J, Joshi A, Gupta M, Yi JH, Chu YW, Shih T, Fang L, Girish S.

Curr Drug Metab. 2012 Sep 1;13(7):911-22.

PMID:
22475266
12.

Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.

Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.

Oncologist. 2016 Apr;21(4):418-24. doi: 10.1634/theoncologist.2015-0321. Epub 2016 Mar 16.

13.

Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial.

Boekhout AH, Gietema JA, Milojkovic Kerklaan B, van Werkhoven ED, Altena R, Honkoop A, Los M, Smit WM, Nieboer P, Smorenburg CH, Mandigers CM, van der Wouw AJ, Kessels L, van der Velden AW, Ottevanger PB, Smilde T, de Boer J, van Veldhuisen DJ, Kema IP, de Vries EG, Schellens JH.

JAMA Oncol. 2016 Aug 1;2(8):1030-7. doi: 10.1001/jamaoncol.2016.1726.

PMID:
27348762
14.

Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.

Ebbing EA, Steins A, Fessler E, Stathi P, Lesterhuis WJ, Krishnadath KK, Vermeulen L, Medema JP, Bijlsma MF, van Laarhoven HWM.

Gastroenterology. 2017 Jul;153(1):63-76.e14. doi: 10.1053/j.gastro.2017.03.004. Epub 2017 Mar 9.

PMID:
28286209
15.

Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

D'Avino C, Paciello R, Riccio G, Coppola C, Laccetti P, Maurea N, Raines RT, De Lorenzo C.

Protein Eng Des Sel. 2014 Mar;27(3):83-8. doi: 10.1093/protein/gzt065. Epub 2014 Jan 12. Erratum in: Protein Eng Des Sel. 2014 May;27(5):177. Coppola, Melina [corrected to Coppola, Carmela].

16.

Functional impairment of human resident cardiac stem cells by the cardiotoxic antineoplastic agent trastuzumab.

Barth AS, Zhang Y, Li T, Smith RR, Chimenti I, Terrovitis I, Davis DR, Kizana E, Ho AS, O'Rourke B, Wolff AC, Gerstenblith G, Marbán E.

Stem Cells Transl Med. 2012 Apr;1(4):289-97. doi: 10.5966/sctm.2011-0016. Epub 2012 Apr 10.

17.

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

Baron JM, Boster BL, Barnett CM.

J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27. Review.

PMID:
24682654
18.

T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.

English DP, Bellone S, Schwab CL, Bortolomai I, Bonazzoli E, Cocco E, Buza N, Hui P, Lopez S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Santin AD.

Cancer Med. 2014 Oct;3(5):1256-65. doi: 10.1002/cam4.274. Epub 2014 Jun 2.

19.

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.

Sadeghi S, Olevsky O, Hurvitz SA.

Pharmgenomics Pers Med. 2014 Oct 15;7:329-38. doi: 10.2147/PGPM.S47524. eCollection 2014. Review.

20.

Ranolazine Attenuates Trastuzumab-Induced Heart Dysfunction by Modulating ROS Production.

Riccio G, Antonucci S, Coppola C, D'Avino C, Piscopo G, Fiore D, Maurea C, Russo M, Rea D, Arra C, Condorelli G, Di Lisa F, Tocchetti CG, De Lorenzo C, Maurea N.

Front Physiol. 2018 Feb 6;9:38. doi: 10.3389/fphys.2018.00038. eCollection 2018.

Supplemental Content

Support Center